AC Immune SA announced three oral presentations highlighting its precision medicine pipeline at the annual Alzheimer’s Association International Conference, AAIC 2024, taking place in Philadelphia, PA, on July 28 – August 1, 2024. These posters include: Discovery and preclinical development of 18FACI-19626, a first-in-class TDP-43-PET tracer; Active immunotherapy, ACI-24.060, induces anti-Abeta antibodies with binding profiles mirroring clinically validated monoclonal antibodies; and A new class of neurodegenerative disease-fighting drugs: morADC.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACIU:
- AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
- AC Immune SA Announces Major Takeda Partnership
- Biotech Alert: Searches spiking for these stocks today
- AC Immune initiated with a Buy at BTIG
- AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024